2 completed, 2 terminated, 2 withdrawn. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Terminated 2, Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow AH 111585: new trials by email Literature Review of AH 111585 trials Research Report on AH 111585
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [18F]Fluciclatide PET Imaging of Pazopanib Response 18F-Fluciclatide - Kidney Neoplasm | Phase 2 | Terminated | Asan Medical Center | 12 | 2013-09-01 | 2016-03-01 |
| RGD-PET-CT in Cancer Angiogenesis 18F-RGD-PET-CT and perfusion CT scans on 3 occasions - Carcinoma, Renal Cell | Phase 2 | Terminated | Oxford University Hospitals NHS Trust | 10 | 2013-05-01 | 2017-11-01 |
| [18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment 18F-Fluciclatide - Kidney Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2012-04-18 | 2019-12-17 | |
| Imaging Studies and the Development of Multiple Myeloma Fluciclatide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2012-03-27 | 2019-12-16 | |
| Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection Fluciclatide Injection - Solid Tumors, High Grade Gliomas | Phase 2 | Completed | GE Healthcare | 70 | 2009-06-01 | 2014-06-09 |
| A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Fluciclatide Injection - (AH111585 (F18)) - High-grade Glioma, Lung Cancer | Phase 2 | Completed | GE Healthcare | 33 | 2007-11-01 | 2014-08-18 |
Carcinoma, Renal Cell (2) · Head and Neck Neoplasms (2) · Kidney Neoplasms (2) · Lung Neoplasms (2) · Sarcoma (2) · Breast Neoplasms (1) · Glioma (1) · Melanoma (1) · Monoclonal Gammopathy of Undetermined Significance (1) · Multiple Myeloma (1) · Smoldering Multiple Myeloma (1)
GE Healthcare (2) · National Cancer Institute (NCI) (2) · Asan Medical Center (1) · Oxford University Hospitals NHS Trust (1)
United States (2) · South Korea (1) · United Kingdom (1)
Jeffrey Winick, Ph.D. (2) · Carl O Landgren, M.D. (1) · Fergus Gleeson (1) · Jin-Sook Ryu, MD. PhD. (1) · Maria Liza Lindenberg, M.D. (1)